NCT01455571CompletedPhase 1
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B
Hanmi Pharmaceutical Company Limited1 site in 1 country55 target enrollmentStarted: November 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 55
- Locations
- 1
- Primary Endpoint
- MTD determination
Study Overview
Brief Summary
The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B.
Detailed Description
Besides the main objective, there are 3 other objectives as follows:
- To determine dose-limiting toxicity (DLT) of HM781-36B
- To characterize the pharmacokinetics of HM781-36B, following oral administration of HM781-36B
- To evaluate anticancer activity of HM781-36B in patients with advanced solid malignancies Groups of 3 patients per cohort or dose level will be treated with escalating doses of HM781-36B
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically confirmed advanced solid tumor 2) Patients who have experienced progressive disease despite of conventional anticancer therapy. Patients who cannot expect effective treatment or prolonged survival with conventional anticancer therapy 3) Previous chemotherapy, radiotherapy and surgical operation are allowed if they are discontinued for at least 4 weeks prior to D0 and all adverse events are resolved 4) Aged ≥19 5) Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2 6) A life expectancy greater than 12 weeks 7) Adequate bone marrow (WBC≥4,000/mm3 platelet≥100000/mm3, hemoglobin≥9.0g/dl and ANC≥ 1500/mm3, renal (Creatinine≤1.5mg/dl) and liver function (AST/ALT/ALP ≤ 3 x upper limit of normal and total bilirubin≤2mg/dl) and no abnormal heart and lung function However, AST/ALT/ALP ≤ 5 x upper limit of normal for patients with liver metastases and ALP level ≤ 5 x upper limit of normal for patients with bone metastases are allowed 8)Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures
Exclusion Criteria
- •Patients with hematopoietic malignancies,uncontrolled infection, ileus, CNS metastasis.
- •Patients who have undergone hematopoietic stem cell transplantation (HSCT) or are candidates for planned HSCT 3) Class III or IV heart failure (NYHA Class) or LVEF<40% 4) Patients who have GI malabsorption or difficulty taking oral medication 5) Patients who have psychiatric or congenital disorder 6) Subjects who, in the investigator's opinion, cannot be treated per protocol due to functional impairments 7) Pregnant or breast-feeding patients; Women of childbearing potential without adequate contraception (Men must use adequate contraception.) 8) Subjects who have no intention of following the requirements of the protocol or the follow-up management. Subjects who cannot be followed up regularly due to psychological, social, family, logistic, and geographical reasons 9) Subjects who were administered with other investigational products within 30 days before screening.
- •Subjects who, in the investigator's opinion, cannot be participated.
Arms & Interventions
HM781-36B
Experimental
Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
Intervention: HM781-36B (Drug)
Outcomes
Primary Outcomes
MTD determination
Time Frame: Dose limiting Toxicity will be evaluated on Day 21 during Cycle 1
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid TumorsAdvanced Solid MalignanciesNCT01455584Hanmi Pharmaceutical Company Limited20
Completed
Phase 1
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573NeoplasmsNCT02405065Hanmi Pharmaceutical Company Limited72
Completed
Phase 1
A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)TumorsNCT00127127Merck Sharp & Dohme LLC18
Terminated
Phase 1
TKI258 in Subjects With Refractory or Relapsed Multiple MyelomaMultiple MyelomaNCT00243763Novartis64
Completed
Phase 1
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic CarcinomaNeoplasms, LiverNCT00629759Jennerex Biotherapeutics14